Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global Seamless Metal Pipes Market Size, Share, Trends, and Forecast 2021-2031 | Hydrogen, Aerospace, and Infrastructure Investment Unlock 4%-6% CAGR OpportunitiesTarget high-margin alloy and stainless pipes for hydrogen, aerospace, pharma and water upgrades; localize supply to capture reshoring demand and reduce raw-material risk.
- Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American InjectablesEnsera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing...
- Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesCompanies: Boehringer IngelheimCompany announcement – No. 52 / 2026
- Defence Therapeutics Inc.Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug ConjugatesDefence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.World ADC San Diego is a leading global forum dedicated to antibody-drug...
- Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditionsCompanies: Roche HoldingBasel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3
- Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKDMironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
- Fresenius completa la adquisición de mAbxience, creando una plataforma más sólida para la futura expansión de su cartera de productosCompanies: Fresenius SE & Co. KGaAmAbxience ha anunciado hoy que Fresenius SE & Co. KGaA ha adquirido el 45% restante de mAbxience a Insud Pharma, consolidando así la exitosa...
- mAbxienceFresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansionCompanies: Fresenius SE & Co. KGaAThe transaction builds on the successful partnership between Fresenius and mAbxience established in 2022. Full ownership creates a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to high-quality biosimilars....
- Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global GrowthEmerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the...
- Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico- La publicación en esta prestigiosa revista, tras un riguroso proceso de revisión por parte de otros expertos del sector, avala el estudio VIRAGE y respalda la evaluación continuada de VCN-01 en el tratamiento del cáncer de páncreas metastásico -
- Jenny McCarthy Begins Therapeutic Plasma Exchange Journey to Address Mold Toxicity and Environmental ToxinsHealth advocate partners with MDLifespan to document her physician-led Advanced Therapeutic Plasma Exchange (TPE) journey and educate others living with ch
- The Rosen Law Firm PAROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...